Idenix Pharmaceuticals, Inc.

Centre National De La Recherche Scientifique

Universitè De Montpellier

L'université Montpellier II

Université Montpellier 2 Sciences Et Techniques

Claire Pierra

Cyril B Dousson

Dominique Surleraux

Gilles J Gosselin

David Dukhan

Francois-Rene Alexandre

Christophe Parsy

Jean-Pierre Sommadossi

Adel M Moussa

Benjamin Alexander Mayes

Jean-Laurent Paparin

Christian Perigaud

Suzanne Peyrottes

Alistair James Stewart

Houcine Rahali

Thierry Convard

Daniel Da Costa

Jean-Francois Griffon

Frederic Leroy

Gilles Gosselin

Guillaume Brandt

Michel Derock

Jerome Peyronnet

Arlène Roland

Jean-François Griffon

Christophe Claude Parsy

Francois-René Alexandre

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2'-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.

2'-chloro nucleoside analogs for HCV infection

Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein: PD, X, R, R, R, and Rare as described herein.

D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease

Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, provided herein are compounds according to Formula I: or a pharmaceutically acceptable salt, solvate, tautomeric or polymorphic form thereof.

Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3'-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Baseand Baseare as provided herein.

3'-deoxy nucleosides for the treatment of HCV

Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

Compounds and pharmaceutical compositions for the treatment of viral infections

Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. 

5,5-fused arylene or heteroarylene hepatitis C virus inhibitors

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

3',5&#x2032;-cyclic phosphoramidate prodrugs for HCV infection

Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

Provided herein are phosphothiophene and phosphothiazole compounds, for example, of any of Formulae I, IA, IIA, IIIA, IVA, VA, VIA, VIIA, IB, IIB, IIIB, IVB, VB, VIB and VIIB disclosed herein, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host infected with HCV.

Phosphothiophene and phosphothiazole HCV polymerase inhibitors

Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formulas IV, IV', I&#x2033;, II&#x2033;, or IVa, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Phosphadiazine HCV polymerase inhibitors IV

Growing community of inventors

Montarnaud, France

Claire Pierra